Showing 4711-4720 of 6803 results for "".
- Mustela Introduces Skin-Soothing PJs for Eczema-Prone Babies and Toddlershttps://practicaldermatology.com/news/mustela-introduces-skin-soothing-pjs-for-eczema-prone-babies-and-toddlers/2459885/The Global Wellness Institute recently cited smart and healing fashion as one of the biggest trends in wellness, and the new Mustela
- FDA Proposes New Sunscreen Regulations; Experts Reacthttps://practicaldermatology.com/news/fda-proposes-new-sunscreen-regulations-experts-react/2459889/The FDA is updating its position on over-the-counter sunscreens, and according to the
- Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rxhttps://practicaldermatology.com/news/applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx/2459904/Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s
- EWG VERIFIED Goes Mainstream with Herbal Essences Shampooshttps://practicaldermatology.com/news/ewg-verified-goes-mainstream-with-herbal-essences-shampoos/2457544/
- Encore Dermatology Announces Phase 2 Safety Data for Impoyzhttps://practicaldermatology.com/news/encore-dermatology-announces-phase-2-safety-data-for-impoyz/2457496/A Phase 2, open-label study published in SKIN The Journal of Cutaneous Medicine, found that subjects treated with Impoyz (clobetasol propionate) Cream, 0.025% showed significantly lower mean post-treatment clobetasol propionate plasma concentrations versus the subjects treated with Temov
- Psoriasis Plus Hypertension Equals Greater Need for Heart Surgeryhttps://practicaldermatology.com/news/psoriasis-plus-hypertension-equals-greater-need-for-cardiovascular-interventions/2457559/Patients with psoriasis and hypertension need more cardiovascular procedures and surgeries than hypertensive patients without psoriasis, a new study in the Journal of Dermatology suggests. In 5.62 year
- UCB: Study Data for Cimzia and Bimekizumab Presented at EADVhttps://practicaldermatology.com/news/ucb-data-for-cimzia-and-at-eadv/2457606/UCB has presented new findings on Cimzia® (certolizumab pegol) and one of its key pipeline molecules, bimekizumab, for the treatment of moderate-to-severe chronic plaque psoriasis (PSO), along with findings from an international survey on physicians’ perceptions about treating women wit
- Allergan Launches Spotlyte: Digital Hub Will Educate Consumers About Medical Aesthetic Treatmentshttps://practicaldermatology.com/news/allergan-launches-spotlyte/2457615/Allergan has launched Spotlyte, described as an innovative digital hub of curated content that helps consumers discover how medical aesthetic treatments may fit into their routines.
- Demand for Vegan Cosmetics Expected to Soarhttps://practicaldermatology.com/news/demand-for-vegan-cosmetics-to-soar-bi-2025/2457631/The global vegan cosmetics market size is projected to reach $20.8 billion by 2025, progressing at a Compound Annual Growth Rate (CAGR) of 6.3 percent during the forecast period. Spiraling demand for vegan cosmetics among millennials is one of the primary growth stimulants of the market,
- Breaking News: Galderma Skinpact Awards Deadline Extended!https://practicaldermatology.com/news/breaking-news-galderma-skinpact-awards-deadline-extended/2457683/The new deadline for the Galderma Skinpact Awards is July 31, 2018. The awards are a social responsibility program by Galderma International in partnership with the Canadian Dermatology Association, and the Women's Dermatolo